Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs ...

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

Several studies have been done on the myriad list of side effects that come from popular weight loss drugs.  A new study ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Taking medications like Ozempic and Wegovy may lead to more hair loss than other weight loss drugs, new research found.

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...